BSE · 524572
Pharmaids Pharmaceuticals Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹3 Cr with net profit ₹-1 Cr — a -48.7% net margin, versus -374.7% the period before.
Shareholding
As of 2026-06-30
- Promoter32.99%
- Public67.01%
8,632 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.66× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — LT-ASM · ASM 1. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #28 of 50 by market cap · medians across 41 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,85,608 Cr | 84.69 | 22.07 | 25.49% | 15.55% |
| Ajanta Pharma Limited | ₹42,115 Cr | 157.89 | 9.33 | 23.33% | 19.37% |
| Gland Pharma Limited | ₹41,522 Cr | 113.08 | 4 | 9.92% | 15.98% |
| Rubicon Research Limited | ₹25,126 Cr | 325.88 | 19.54 | 19.14% | 14.07% |
| Caplin Point Laboratories Ltd. | ₹19,725 Cr | 115.95 | 5.5 | 17.88% | 29.32% |
| Eris Lifesciences Limited | ₹19,627 Cr | 68.76 | 5.03 | 15.87% | 19.89% |
| Shilpa Medicare Ltd. | ₹11,858 Cr | 110.04 | 4.58 | 9.39% | 15.81% |
| Marksans Pharma Limited | ₹11,794 Cr | 79.59 | 3.9 | 13.82% | 14.16% |
| Senores Pharmaceuticals Limited | ₹6,130 Cr | 167.21 | 6.57 | 12.36% | 18.32% |
| Bliss GVS Pharma Ltd. | ₹4,848 Cr | 141.97 | 4.05 | 8.95% | 11.15% |
| Pharmaids Pharmaceuticals Ltd.(this company) | ₹106 Cr | — | 2.22 | -29.76% | -42.04% |
AI analysis
AI-generated · google/gemini-2.5-flashPharmaids Pharmaceuticals Ltd. (524572) has a market capitalization of Rs 112 Cr. The company reported a profit margin of -42.04% and an EPS of 0. The debt-to-equity ratio stands at 0.36. As of June 30, 2026, promoter shareholding was 32.99%, with public shareholding at 67.01%.
Positives
- +The debt-to-equity ratio is 0.36, indicating relatively lower leverage.
- +The book value per share is Rs 13.51.
Negatives
- −The company reported an annual net loss of Rs 10.78 Cr in March 2025 and a quarterly net loss of Rs 1.81 Cr in March 2026.
- −The profit margin is significantly negative at -42.04%.
- −Return on equity (ROE) is -29.76% and return on capital employed (ROCE) is -20.97%.
- −The company has been placed under LT-ASM surveillance, specifically ASM Stage 1.
- −The earnings per share (EPS) is 0.
Financial performance
The company reported annual revenue of Rs 19.55 Cr in March 2025, with a net loss of Rs 10.78 Cr for the same period. Quarterly results for March 2026 showed revenue of Rs 7.18 Cr and a net loss of Rs 1.81 Cr. The EBITDA for March 2026 was -0.72.
Profitability & returns
Pharmaids Pharmaceuticals Ltd. experienced negative profitability metrics. The Roe was -29.76% and Roce was -20.97%. The company reported a negative profit margin of -42.04%, indicating that it operated at a loss relative to its revenue. The EPS as of the latest available data is 0.
Balance sheet
The book value per share is Rs 13.51. The company maintains a debt-to-equity ratio of 0.36. This indicates the proportion of debt used to finance its assets relative to shareholder equity.
Ownership & pledges
As of June 30, 2026, promoters held 32.99% of the company's shares. Public shareholding was 67.01%. There were no shares pledged by the promoters. Over the last few years, the number of shareholders has increased from 4618 in March 2018 to 8632 in June 2026.
Regulatory & surveillance
Pharmaids Pharmaceuticals Ltd. is currently under LT-ASM surveillance, specifically categorized under ASM Stage 1. This indicates that the stock has met certain criteria that warrant closer monitoring by regulatory bodies.
Data as of — price: 2026-07-29 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Pharmaids Pharmaceuticals Ltd.share price & fundamentals